Diacerein (cas 13739-02-1) inhibits Estradiol-benzoate induced cervical hyperkeratosis in female rats
-
Add time:09/25/2019 Source:sciencedirect.com
Cervical hyperkeratosis is a common gynecological lesion and usually caused by inflammation or trauma. We investigated the effect of Diacerein (cas 13739-02-1) on Estradiol benzoate-induced cervical hyperkeratosis. Diacerein (50 mg/kg/day) was given orally to rats for 4 weeks in the presence or absence of cervical hyperkeratosis induced by intramuscular injection of Estradiol benzoate (60 μg/100 g) 3 times per week for 4 weeks. We measured the serum levels of total cholesterol, uterine weights, uterine tissue malondialdehyde, total nitrites, superoxide dismutase activity, caspase-3, interleukin-1b immunoexpression and histopathology. Our results showed that Estradiol benzoate succeeded to induce cervical hyperkeratosis which was detected by typical histopathological changes. In addition; there was significant reduction in superoxide dismutase levels and caspase-3 immunoexpression but significant increase in serum total cholesterol, malondialdehyde, total nitrites and interleukin-1b immunoexpression. Diacerein could improve all measured parameters to normal levels. It markedly prevented cervical hyperkeratosis through its anti-inflammatory (IL-1b receptor inhibitor), antioxidant and anti-apoptotic effects.
We also recommend Trading Suppliers and Manufacturers of Diacerein (cas 13739-02-1). Pls Click Website Link as below: cas 13739-02-1 suppliers
Prev:Mechanical exposure and Diacerein (cas 13739-02-1) treatment modulates integrin-FAK-MAPKs mechanotransduction in human osteoarthritis chondrocytes
Next:Original ArticleValidated determination of Diacerein (cas 13739-02-1) and its active metabolite, rhein, by stability indicating constant pattern method as a novel manipulation of zero order spectra) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Pharmacological treatment with Diacerein (cas 13739-02-1) combined with mechanical stimulation affects the expression of growth factors in human chondrocytes09/29/2019
- Formulation and optimization of niosomes for topical Diacerein (cas 13739-02-1) delivery using 3-factor, 3-level Box-Behnken design for the management of psoriasis09/28/2019
- Original articleDiacerein (cas 13739-02-1) orphan drug development for epidermolysis bullosa simplex: A phase 2/3 randomized, placebo-controlled, double-blind clinical trial10/01/2019
- Original articleDiacerein (cas 13739-02-1) alleviates kidney injury through attenuating inflammation and oxidative stress in obese insulin-resistant rats09/27/2019
- Original ArticleValidated determination of Diacerein (cas 13739-02-1) and its active metabolite, rhein, by stability indicating constant pattern method as a novel manipulation of zero order spectra09/26/2019
- Mechanical exposure and Diacerein (cas 13739-02-1) treatment modulates integrin-FAK-MAPKs mechanotransduction in human osteoarthritis chondrocytes09/24/2019
- Diacerein (cas 13739-02-1) protects against glycerol-induced acute kidney injury: Modulating oxidative stress, inflammation, apoptosis and necroptosis09/10/2019
- Novel spectrophotometric methods for the determination of Leflunomide and Diacerein (cas 13739-02-1) in binary mixtures09/09/2019
- Original articlePharmacokinetics and bioequivalence study of rhein as the main metabolite of Diacerein (cas 13739-02-1)09/08/2019